Trojer Patrick 4

4 · CONSTELLATION PHARMACEUTICALS INC · Filed Nov 8, 2019

Insider Transaction Report

Form 4

Period: 2019-11-06

CONSTELLATION PHARMACEUTICALS INCCNST

Trojer Patrick

Chief Scientific Officer

Transactions

Exercise/Conversion
Common Stock
2019-11-06$4.08/sh+195$796→ 8,417 total
Exercise/Conversion
Common Stock
2019-11-06$5.51/sh+801$4,414→ 9,218 total
Exercise/Conversion
Common Stock
2019-11-06$5.51/sh+8,641$47,612→ 17,859 total
Exercise/Conversion
Common Stock
2019-11-06$5.62/sh+18,765$105,459→ 36,624 total
Exercise/Conversion
Common Stock
2019-11-06$7.60/sh+5,786$43,974→ 42,410 total
Exercise/Conversion
Common Stock
2019-11-06$8.04/sh+2,893$23,260→ 46,142 total
Exercise/Conversion
Stock Option (Right to Buy)
2019-11-06−2,893→ 43,387 total
Exercise: $8.04Exp: 2028-04-22→ Common Stock (2,893 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2019-11-06−8,641→ 17,312 total
Exercise: $5.51Exp: 2027-02-16→ Common Stock (8,641 underlying)
Exercise/Conversion
Common Stock
2019-11-06$7.60/sh+839$6,376→ 43,249 total
Sale
Common Stock
2019-11-06$30.16/sh−11,535$347,843→ 0 total
Exercise/Conversion
Stock Option (Right to Buy)
2019-11-06−195→ 0 total
Exercise: $4.08Exp: 2022-03-06→ Common Stock (195 underlying)
Sale
Common Stock
2019-11-06$20.01/sh−11,535$230,797→ 34,607 total
Exercise/Conversion
Stock Option (Right to Buy)
2019-11-06−839→ 850 total
Exercise: $7.60Exp: 2026-02-18→ Common Stock (839 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2019-11-06−5,786→ 40,494 total
Exercise: $7.60Exp: 2028-03-05→ Common Stock (5,786 underlying)
Sale
Common Stock
2019-11-06$25.06/sh−23,072$578,214→ 11,535 total
Exercise/Conversion
Stock Option (Right to Buy)
2019-11-06−18,765→ 2,836 total
Exercise: $5.62Exp: 2025-11-08→ Common Stock (18,765 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2019-11-06−801→ 3,121 total
Exercise: $5.51Exp: 2027-07-10→ Common Stock (801 underlying)

Footnotes (11)

[F1]These trades were made pursuant to a Rule 10b5-1 trading plan.
[F10]This option was granted on July 11, 2017, and the shares underlying the options vest in equal quarterly installments through July 11, 2021.
[F11]This option was granted on March 7, 2012, and is fully vested.
[F2]This transaction was executed in multiple trades at prices ranging from $20.00 to $20.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
[F3]This transaction was executed in multiple trades at prices ranging from $25.00to $25.51. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
[F4]This transaction was executed in multiple trades at prices ranging from $30.00 to $30.84. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
[F5]This option was granted on April 23, 2018, and the shares underlying the options vest in equal quarterly installments through April 23, 2022.
[F6]This option was granted on February 19, 2016, and the shares underlying the options vest in equal quarterly installments through February 19, 2020.
[F7]This option was granted on March 6, 2018, and the shares underlying the options vest in equal quarterly installments through March 6, 2022.
[F8]This option was granted on November 9, 2015, and is fully vested.
[F9]This option was granted on February 17, 2017, and the shares underlying the options vest in equal quarterly installments through February 17, 2021.

Documents

1 file

4
primarydocument.xmlPrimary
PRIMARY DOCUMENT